CLOs on the Move

Neoleukin

www.neoleukin.com

 
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.neoleukin.com
  • 188 East Blaine Suite 450
    Seattle, WA USA 98102
  • Phone: 855.226.6447

Executives

Name Title Contact Details
Holly Vance
General Counsel Profile
Donna Cochener
General Counsel Profile
Donna Cochener
Interim Chief Executive Officer, Senior Vice President of Legal and General Counsel Profile
Leslie Aberman
Vice President of Legal Affairs and Intellectual Property Profile

Similar Companies

http://www.katumbas.com/

http://www.katumbas.com/ is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Onconano Medicine

OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.

Avelas Biosciences

Avelas Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MARATHONLS

Marathon Life Sciences Laboratory Solutions at the Speed of Science Learn more Our Lab Supplies Line Cell Strainer Download Catalogadd to cart Tissue Culture Plates Download Catalog 15/50mL Centrifuge Tubes Download Catalog Petri Dishes Download Catalo...

Seismic Therapeutic

We are The Machine Learning Immunology Company. Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics drug discovery and development process. Using our IMPACT™ platform, we are fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies for patients. Seismic Therapeutic has an emerging pipeline of novel approaches to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub.